Pharma's Almanac

Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman

Nice Insight — Fri, 27 Sep 2019 16:42:49 GMT

NEW YORK--(BUSINESS WIRE)-- Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to retire on December 31, 2019, and that it has unanimously elected Pfizer’s Chief Executive Officer (CEO), Dr. Albert Bourla, to succeed him as Chairman of the Board of Directors effective January 1, 2020. Bourla will also retain the CEO role.

Amgen Announces Positive Results From Two Phase 3 BLINCYTO® Studies In Pediatric Patients

Nice Insight — Fri, 27 Sep 2019 09:00:00 GMT

Phase 3 '215 and Children's Oncology Group (COG) Studies Both Stopped Early Due to Treatment Benefit of BLINCYTO Over Chemotherapy

Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets

Nice Insight — Fri, 27 Sep 2019 09:00:00 GMT

Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity while testing the below finished product batches manufactured utilizing active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited using the old Route of Synthesis. The recall is expanded to include an additional 3 lots of Losartan Potassium Tablets USP and 2 lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP.

DataArt’s Healthcare & Life Sciences Practice Launches “SkinCareAI” Prototype App for Early Melanoma Detection

Nice Insight — Fri, 27 Sep 2019 09:00:00 GMT

Global technology consultancy DataArt announced today the launch of “SkinCareAI” - a prototype app that analyses skin images to detect early signs of melanoma.

GENEWIZ Celebrates Opening of European Headquarters in Germany

Nice Insight — Thu, 26 Sep 2019 09:00:00 GMT

LEIPZIG, Germany -- Leading global genomics services provider, GENEWIZ, a Brooks Life Sciences Company, announced the opening of its European headquarters for its genomics business in Leipzig, Germany. This centralized location will help accelerate the innovation and development of genomics research and applications in pharmaceutical, biotechnology, agriculture, environmental, clean energy, academic, and other related areas in Europe. It includes a 1,500 square metre biomolecular high-tech laboratory equipped with state-of-the-art sequencing and automation technologies.

GSK Invests $120 million in Next-generation US Biopharmaceutical Manufacturing Facility

Nice Insight — Wed, 25 Sep 2019 09:00:00 GMT

Part of nearly $400 million in US manufacturing investments to deliver on the company’s pipeline and bring medicines to patients faster.

FDA Announces Voluntary Recall of Sandoz Ranitidine Capsules Following Detection of an Impurity

Nice Insight — Tue, 24 Sep 2019 09:00:00 GMT

The U.S. Food and Drug Administration is alerting health care professionals and patients of a voluntary recall of 14 lots of prescription ranitidine capsules distributed by Sandoz Inc., used to decrease the amount of acid created by the stomach. This recall is due to a nitrosamine impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled medicine. NDMA is classified as a probable human carcinogen (a substance that could cause cancer).

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Disease

Nice Insight — Mon, 23 Sep 2019 09:00:00 GMT

Boehringer Ingelheim strengthens its retinal disease pipeline portfolio with new co-development and license agreement
The partners aim to develop novel therapies with significantly reduced patient burden for eye diseases with limited or only insufficient treatment options using Inflammasome Therapeutics’ intravitreal drug delivery technology
Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization

Ingelheim, Germany and Newton, MA, USA – Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases.

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

Nice Insight — Fri, 20 Sep 2019 20:22:04 GMT

NEW YORK, (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”).

Several Candidates are Contending for the Top FDA Job

Nice Insight — Fri, 20 Sep 2019 16:41:39 GMT

Acting Commissioner Ned Sharpless has competition.

Pharma's Almanac

Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman

Amgen Announces Positive Results From Two Phase 3 BLINCYTO® Studies In Pediatric Patients

Phase 3 '215 and Children's Oncology Group (COG) Studies Both Stopped Early Due to Treatment Benefit of BLINCYTO Over Chemotherapy

Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets

DataArt’s Healthcare & Life Sciences Practice Launches “SkinCareAI” Prototype App for Early Melanoma Detection

GENEWIZ Celebrates Opening of European Headquarters in Germany

GSK Invests $120 million in Next-generation US Biopharmaceutical Manufacturing Facility

FDA Announces Voluntary Recall of Sandoz Ranitidine Capsules Following Detection of an Impurity

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Disease

Boehringer Ingelheim strengthens its retinal disease pipeline portfolio with new co-development and license agreement

The partners aim to develop novel therapies with significantly reduced patient burden for eye diseases with limited or only insufficient treatment options using Inflammasome Therapeutics’ intravitreal drug delivery technology

Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

Several Candidates are Contending for the Top FDA Job